Syngene Intl looks to diversify revenue as single biologics programme weighs on performance
Company says influence of one biologics client played through its December quarter numbers, but stressed that performance outside this programme remained stable across manufacturing and research services.
Company says influence of one biologics client played through its December quarter numbers, but stressed that performance outside this programme remained stable across manufacturing and research services.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
